News Roche’s Tecentriq combo extends life in advanced NSCLC Roche has announced that its phase 3 IMpower130 study met its co-primary endpoints of overall survival and progression-free survival in non-small cell lung cancer (NSCLC).
Views & Analysis ASCO 2018 Preview – what to expect from this year’s conferen... pharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the year for cancer medicine.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
